Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Longer treatment duration, using semaglutide, higher percentage body fat, and nondiabetic status may be associated with better weight reduction.

A large network meta-analysis ranked eight GLP-1 receptor agonists for glycemic, weight, and safety outcomes in adults with type 2 diabetes. Tirzepatide demonstrated the greatest efficacy for glucose ...

Compared with DPP-4i, SGLT2i reduced the composite pulmonary endpoint overall, prevented COPD hospitalizations primarily in fit or mildly frail patients, and conferred protection against pneumonia ...

While GLP-1 RA use was associated with a lower risk of delirium in the early treatment period, this advantage disappeared with long-term use and metformin remained associated with superior survival.

Innovent Biologics Inc. announced June 27 that it gained National Medical Products Administration’s (NMPA) approval of mazdutide as a new weight loss therapy for obese or overweight patients in China.

U.K. regulators have launched a study into a possible genetic link between use of GLP-1s, such as Ozempic, Mounjaro and Wegovy, and acute pancreatitis. Yellow Card Biobank, a joint initiative of ...

Findings also show improved persistence with high-potency, obesity-approved GLP-1 products In addition to persistence and adherence insights, the Year-3 study found 38% of individuals switched GLP ...